AbCellera Biologics Azioni (NASDAQ: ABCL)

Ultime notizie per AbCellera Biologics (NASDAQ:ABCL) Azioni

AbCellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Inc

The U.S. trade deficit widened sharply to an all-time high in March as American companies rushed to import foreign goods ahead of President Donald Trump&#8216;s sweeping new trade tariffs. This move triggered a rush of orders and <a href="https://www.benzinga.com/topic/tariffs">skewed international trade flows.</a>
According to data released Monday by the U.S. Bureau of Economic Analysis and the Census Bureau, the trade deficit surged 14% from a revised $123.2 billion in February to $140.5 billion in March, the most significant monthly gap ever recorded.
The spike was driven by a 4.4% jump in imports to $419 billion, while exports rose just 0.2% to $278.5 billion.
<h3 class="wp-block-heading">March Trade Data Shows Imports Far Outpacing Exports</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>U.S. Trade Deficit (March):</td>
<td>$140.5 Billion</td>
<td>+14.0%</td>
</tr>
<tr>
<td>U.S. Exports (March):</td>
<td>$278.5 Billion</td>
<td>+0.2%</td>
</tr>
<tr>
<td>U.S. Imports (March):</td>
<td>$419.0 Billion</td>
<td>+4.4%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Import Surge Fueled By Tariff Fears</h3>
The March data likely reflect a wave of frontrunning, a strategy in which businesses accelerate shipments to anticipate policy changes.
On April 2, the Trump administration announced a sweeping tariff package targeting all trading partners, which sent ripples through global supply chains and financial markets. Just one week later, the White House introduced a 90-day pause to allow time for trade negotiations.
Consumer goods imports jumped $22.5 billion in March, driven by a staggering $20.9 billion surge in pharmaceutical preparations, as well as gains in automotive parts, computer accessories, and capital goods. Meanwhile, imports of industrial supplies and materials fell $10.7 billion.
Read Also: <a href="https://www.benzinga.com/news/global/25/05/45215257/bill-ackman-calls-tariffs-a-one-time-reset-warns-prolonged-china-fight-could-drag-market-slump-to-q2">Bill Ackman Calls Tariffs A &#8216;One Time Reset,&#8217; Warns Prolonged China Fight Could Drag Market Slump To Q2</a>
<h3 class="wp-block-heading">Record Goods Deficit, Weak Services Surplus</h3>
The goods deficit alone ballooned by $16.5 billion to $163.5 billion, while the services surplus shrank $800 million to $23.0 billion.
Year-to-date, the total trade deficit has soared 92.6% from the same period in 2024, totaling an additional $189.6 billion as import growth of 23.3% continues to far outpace exports, which rose by 5.2%.
The trade gap expanded to $131.4 billion on a three-month moving average basis, up $14.1 billion from February. Imports averaged $407.1 billion, while exports averaged $275.7 billion.
<h3 class="wp-block-heading">European Union, China, Mexico Lead Deficit Expansion</h3>
Country-level data revealed deficits with the European Union at $48.3 billion, Ireland at $29.3 billion, and China at $24.8 billion.
The deficit with Ireland surged by $15.3 billion, primarily due to a sharp increase in pharmaceutical imports — a potential reflection of rushed purchases by U.S. health companies ahead of expected cost increases under the tariffs.
Deficits with France rose by $2.4 billion and with Mexico by $1.5 billion. The deficit with Switzerland, by contrast, narrowed by $4.1 billion due to a notable drop in imports.
<h3 class="wp-block-heading">Export Trends Remain Soft</h3>
Goods exports rose modestly by $1.3 billion to $183.2 billion in March, with notable gains in natural gas, nonmonetary gold, and automotive vehicles. Yet, capital goods exports declined $1.5 billion, weighed down by a $1.8 billion drop in civilian aircraft.
Services exports dipped $900 million to $95.2 billion, largely driven by a $1.3 billion decline in travel services. This decline is possibly tied to weaker demand in tourism-related sectors amid higher international costs and lingering economic uncertainty.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45205780/sp-500-stocks-that-defy-sell-in-may-myth-5-companies-with-strong-historical-gains">S&amp;P 500 Stocks That Defy &#8216;Sell In May&#8217; Myth: 5 Companies With Strong Historical Gains</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Econ #s

Economics

US Trade Deficit Soars To Record $140B As Imports Rocket Ahead Of Trump's Tariffs

News

USA Redbook (YoY)	6.9% Vs 6.1% Prior

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) European woes continue to pose a problem for Elon Musk&#8217;s EV giant as sales in the UK and Germany hit new lows.
What Happened: Sales for the company's vehicles fell by over 62% in the UK compared to last year and declined 46% YoY in Germany, according to a report published by Reuters on Tuesday.
This decline in sales follows a trend for the company in Europe, with sales plunging in some other markets within the region. Tesla's share in the European market also declined to 2%, from 2.9% last year.
Why It Matters: Musk's company sold over 512 vehicles in April, compared to 1,352 units last year in the UK. Interestingly, Tesla <a href="https://www.benzinga.com/markets/25/05/45192200/teslas-european-woes-deepen-as-new-car-sales-for-april-plunge-in-spain-as-chinese-rivals-soar">sold over 571 units</a> in Spain, a 36% decline, according to data released by experts.
Tesla's sales in the region have taken a hit in Europe, even as EVs have seen <a href="https://www.benzinga.com/25/04/44975755/tesla-sales-decline-28-in-europe-as-ev-car-market-experiences-growth-report">greater adoption from drivers</a> in the region. Sales for BEVs rose 17.1% in the region, ACEA data shows.
The company also faces stiff competition from rivals in the region, with Chinese EV giant BYD Co. Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) experiencing <a href="https://www.benzinga.com/news/global/25/05/45202597/tesla-stock-falls-on-european-sales-decline-rising-competition-whats-going-on">triple-digit growth</a> in sales. BYD also pivoted its European strategy earlier and is all set to produce vehicles in the region with a manufacturing <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">facility in Hungary</a>.
The decline in sales for Tesla comes as Musk's endorsement of far-right political ideals has resulted in backlash against the billionaire as well as his company's products being at the receiving end of vandalism.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44945220/chinas-geely-announces-it-will-share-battery-safety-patents-safety-lab-with-the-auto-industry">China&#8217;s Geely To Share Battery Safety Patents, Unveils World&#8217;s Largest EV Safety Lab At Shanghai Auto Show</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

Markets

Tech

General

BYDDF

BYDDY

TSLA

Tesla New Car Sales Hit 2-Year Low In UK, Germany As European Woes Continue

BMO Capital analyst Benjamin Mayhew initiates coverage on Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) with a Market Perform rating and announces Price Target of $100.

Price Target

Initiation

Analyst Ratings

CALM

BMO Capital Initiates Coverage On Cal-Maine Foods with Market Perform Rating, Announces Price Target of $100

WIIM

Brazil Potash shares are trading higher after the company announced it agreed to establish an equity line of credit with Alumni Capital to progress its flagship Autazes potash project.

ACTU

Actuate Therapeutics shares are trading higher after the company announced elraglusib combined with GnP met its primary endpoint in its ongoing Phase 2 trial.

Expeditors Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NASDAQ">EXPD</a>) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.37 by 7.3 percent. This is a 25.64 percent increase over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $2.67 billion which beat the analyst consensus estimate of $2.56 billion by 4.08 percent. This is a 20.80 percent increase over sales of $2.21 billion the same period last year.

Earnings

Earnings Beats

EXPD

Expeditors Intl Q1 EPS $1.47 Beats $1.37 Estimate, Sales $2.67B Beat $2.56B Estimate

SBET

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

STSS

Sharps Technology shares are trading higher after the company announced it received an approximately $100K initial purchase order from a Hungarian vaccine provider for its Securegard syringes.

Loop Capital analyst Ananda Baruah maintains Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) with a Hold and lowers the price target from $97 to $78.

LOGI

Loop Capital Maintains Hold on Logitech International, Lowers Price Target to $78

CCLD

CareCloud shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 EPS guidance above estimates.

Barclays analyst David Anderson maintains Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) with a Overweight and lowers the price target from $50 to $48.

Barclays Maintains Overweight on Tenaris, Lowers Price Target to $48

CTNT

Cheetah Net Supply Chain shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) is looking for Q3 Adj EPS of $1.25-$1.75 vs $1.63 analyst estimate. sees sales of $715.000 million-$745.000 million vs $746.32 million analyst estimate.

Guidance

ATKR

Atkore Sees Q3 Adj EPS $1.25-$1.75 vs $1.63 Est; Sees Sales $715.000M-$745.000M vs $746.32M Est

STIM

Neuronetics shares are trading lower after the company reported a Q1 EPS miss.

BRCC

BRC shares are trading lower after the company reported a Q1 EPS miss.

Barclays analyst Maurice Patrick maintains Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) with a Equal-Weight and lowers the price target from $12 to $11.

LBTYA

Barclays Maintains Equal-Weight on Liberty Global, Lowers Price Target to $11

ATRA

Atara Biotherapeutics shares are trading higher after the company provided updates on EBVALLO and announced the FDA has lifted its clinical hold to resume the clinical trials.

i3 Verticals, Inc. ("i3 Verticals" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>), and Infinx, Inc. ("Infinx"), a leader in AI-powered revenue cycle management solutions, today announced the entry into a definitive agreement and the contemporaneous closing of the sale of i3 Verticals' Healthcare Revenue Cycle Management ("RCM") business, including its associated proprietary technology, to Infinx, in an all-cash transaction for $96 million, subject to post-closing purchase price adjustments.

IIIV

i3 Verticals Sells Healthcare RCM Business To Infinx In $96M All-Cash Deal

SIFY

Sify's Chennai And Noida Data Center AI Facilities Achieve NVIDIA DGX-Ready Certification

Press Releases

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera Reports Full Year 2024 Business Results

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

ABBV

ABCL

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

AbCellera Biologics

Notizie

Ultime notizie per AbCellera Biologics (NASDAQ:ABCL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO